# Tolvaptan Extension Study in Participants With ADPKD

> **NCT01214421** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 1083 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease (ADPKD)

## Interventions

- **DRUG:** Tolvaptan

## Key facts

- **NCT ID:** NCT01214421
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-26
- **Primary completion:** 2016-02-29
- **Final completion:** 2016-02-29
- **Target enrollment:** 1083 (ACTUAL)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01214421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01214421, "Tolvaptan Extension Study in Participants With ADPKD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01214421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*